NKTR Nektar Therapeutics
Legal ·
A federal jury found that Eli Lilly breached the implied covenant of good faith in a rezpegaldesleukin license with Nektar and awarded $90 million, according to an 8-K filed September 25, 2026. Nektar is also a defendant in a securities class action, Schramke v. Nektar Therapeutics, filed in March 2026.
Nektar will sell up to $150 million of stock through Guggenheim Securities and H.C. Wainwright at a 3.0% commission. The company used $208.5 million in operations in 2025, and its Phase 3 spending is set to rise.
Nasdaq told Nektar on June 24, 2025 that it met the minimum bid rule after a $1.00 closing bid held for 10 consecutive business days. The 8-K gives no share price or financial figures, and the company's pipeline is still in mid-stage trials.
Nektar's board approved the split on May 23, 2025, and trading on a split-adjusted basis is set to begin June 9. The filings give no reason for the split, and a June 6 amendment raised authorized shares to 390,000,000.
Nektar sold the Huntsville plant, certain other related manufacturing assets and certain related liabilities to the buyer under an agreement dated November 1, 2024.
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $117.3 million | $120.9 million |
| Net income (loss) | -$164.1 million | -$119.0 million |
| Cash from operations | -$208.5 million | -$175.7 million |
| Cash and equivalents | $15.1 million | $44.3 million |
| Short-term investments | $230.6 million | $211.0 million |
Our latest story on this, dated Jun 4, 2025: "Nektar sets one-for-fifteen reverse split, effective June 8, 2025". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Sep 25, 2026: "Jury awards Nektar $90 million in Lilly contract case; securities class action pending". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated May 8, 2026: "Nektar Therapeutics sets up $150,000,000 at-the-market stock program". The story links the filing or release it is based on. Read the story.
Nektar Therapeutics trades under the ticker NKTR on NASDAQ.
Nektar Therapeutics is listed on NASDAQ. Our directory also records these other listings: DUS:ITH0; FWB:ITH0; GETTEX:ITH0; HAM:ITH0; HAN:ITH0; LS:A419UB; LSE:0UNL; MUN:ITH0; SWB:ITH0; TRADEGATE:ITH0; XETR:ITH0.
The SEC Central Index Key (CIK) for Nektar Therapeutics is 906709. Its filings are on SEC EDGAR.
34,142,994 shares as of 2026-08-07, per the cover page of its 10-Q filed 2026-08-14.
Our directory records Nektar Therapeutics under United States.
Our directory classifies Nektar Therapeutics as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Nektar Therapeutics is US6402683063.
aibio.space lists Nektar Therapeutics among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
Nektar Therapeutics reported a net loss of $164.1 million for the fiscal year ended Dec 31, 2025, and used $208.5 million of cash in operations, per its annual report to the SEC.
$117.3 million in the fiscal year ended Dec 31, 2025, per its annual report.
$684.3 million in cash and short-term investments at Jun 30, 2026, per its 10-Q.
Reported a financing. SEC Form 8-K (Items 1.01,5.02,9.01). Source
Reported a financing. SEC Form 424B5. Source
Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-K. Source
Reported a financing. SEC Form 424B5. Source
Set up an at-the-market program to sell shares over time. SEC Form 424B5. Source
Reported a financing. SEC Form 424B5. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). Source
Reported a reverse stock split. SEC Form 8-K (Items 8.01). Source
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). Source
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Reported a financing. SEC Form 8-K (Items 1.01,9.01). Source
Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 2.01,9.01). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio